Inflammatory and Noninflammatory Itch: Implications in Pathophysiology-Directed Treatments

Area of Science:

• Dermatology
• Neuroscience
• Immunology

Background:

• Itch is a primary dermatologic complaint, severely affecting patient quality of life.
• Itch signals are transmitted from the skin's cutaneous nerve endings to the brain cortex.
• Both noninflammatory (e.g., uremic pruritus) and inflammatory skin diseases cause itch.

Purpose of the Study:

• To review targeted therapies for inflammatory itch in atopic dermatitis (AD).
• To discuss management of abnormal itch transduction in common itching skin diseases.
• To highlight recent advancements in understanding itch mechanisms and treatment.

Main Methods:

• Literature review of targeted therapies for inflammatory itch.
• Analysis of mechanisms underlying itch in AD and other skin conditions.
• Summary of current and emerging therapeutic strategies.

Main Results:

• Atopic dermatitis (AD) is a prototypic inflammatory skin disease characterized by intense itch.
• Targeted therapies, including monoclonal antibodies against IL-4, IL-13, TSLP, IgE, and IL-31, are being developed for AD itch.
• Promising therapeutic effects have been observed with several targeted agents.

Conclusions:

• Understanding itch mechanisms has led to targeted therapies for AD.
• Monoclonal antibodies and other targeted treatments offer new hope for managing inflammatory itch.
• This review synthesizes current knowledge on managing itch in AD and other skin diseases.